Phibro Animal Health Corporation

The business, in plain English

Phibro Animal Health Corporation booked $1.5B of revenue in FY2026 in the Healthcare sector and kept 33.8% of it as gross profit — a moderate-margin business by that measure. After every other cost, 6.6% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $654M (FY2012) to $1.5B (FY2026) — about 6.2% a year compounded over 14 years.

It earned 43.6% on invested capital in the latest filed year, FY2026. Across the full 14-year measurable filed record, median ROIC was 17.3%. Over the v3 recent window (10 measurable filed years), median ROIC was 14.4%. The Returns on Capital filter above scores it 62/100.

PAHC's latest filed year, FY2026, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Business Trend is the strongest of the five filters (90/100) and Balance-Sheet Safety the weakest (33/100), which is how PAHC lands at 59/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.